IL296168A - Preparations and methods for evaluating the effectiveness of inhibitors of neurotransmitter transporters - Google Patents

Preparations and methods for evaluating the effectiveness of inhibitors of neurotransmitter transporters

Info

Publication number
IL296168A
IL296168A IL296168A IL29616822A IL296168A IL 296168 A IL296168 A IL 296168A IL 296168 A IL296168 A IL 296168A IL 29616822 A IL29616822 A IL 29616822A IL 296168 A IL296168 A IL 296168A
Authority
IL
Israel
Prior art keywords
snp
rsl2217173
treatment
transporter
disorder
Prior art date
Application number
IL296168A
Other languages
English (en)
Hebrew (he)
Original Assignee
Denovo Biopharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denovo Biopharma Llc filed Critical Denovo Biopharma Llc
Publication of IL296168A publication Critical patent/IL296168A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6858Allele-specific amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL296168A 2020-03-06 2021-02-23 Preparations and methods for evaluating the effectiveness of inhibitors of neurotransmitter transporters IL296168A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062986603P 2020-03-06 2020-03-06
PCT/US2021/019265 WO2021178166A1 (en) 2020-03-06 2021-02-23 Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters

Publications (1)

Publication Number Publication Date
IL296168A true IL296168A (en) 2022-11-01

Family

ID=77613738

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296168A IL296168A (en) 2020-03-06 2021-02-23 Preparations and methods for evaluating the effectiveness of inhibitors of neurotransmitter transporters

Country Status (13)

Country Link
US (1) US12612661B2 (https=)
EP (1) EP4106872A4 (https=)
JP (1) JP2023515665A (https=)
KR (1) KR20230005816A (https=)
CN (1) CN115515680A (https=)
AR (1) AR121515A1 (https=)
AU (1) AU2021231683A1 (https=)
BR (1) BR112022017770A2 (https=)
CA (1) CA3174572A1 (https=)
IL (1) IL296168A (https=)
MX (1) MX2022010816A (https=)
TW (1) TW202146660A (https=)
WO (1) WO2021178166A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000019303A1 (it) * 2020-08-05 2022-02-05 Univ Degli Studi Di Brescia Analoghi strutturali del metilfenidato come agenti disease-modifying della malattia di parkinson
CN114848835B (zh) * 2022-03-22 2023-08-25 暨南大学 塞来昔布的聚乙二醇修饰及连接叶酸基团的靶向药物分子及制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6945457B1 (en) * 1996-05-10 2005-09-20 Transaction Holdings Ltd. L.L.C. Automated transaction machine
JP4198582B2 (ja) * 2003-12-02 2008-12-17 独立行政法人科学技術振興機構 タンタルオキシナイトライド酸素還元電極触媒
WO2007128884A1 (en) * 2006-05-09 2007-11-15 Oy Jurilab Ltd Novel genes and markers in type 2 diabetes and obesity
US20080299125A1 (en) 2006-06-05 2008-12-04 Perlegen Sciences, Inc. Genetic basis of treatment response in depression patients
WO2008065544A2 (en) 2006-09-11 2008-06-05 Mcgill University Genetic predictors of risk for type 2 diabetes mellitus
EP2243834A1 (en) 2007-03-05 2010-10-27 Cancer Care Ontario Assessment of risk for colorectal cancer
US20170029892A1 (en) 2009-05-29 2017-02-02 Jay L. Lombard Methods and compositions for the treatment of post-traumatic stress disorder
US8355927B2 (en) * 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
EP2707498B1 (en) 2011-01-31 2018-01-17 Denovo Biomarkers Inc. Method for discovering pharmacogenomic biomarkers
WO2012156515A1 (en) * 2011-05-18 2012-11-22 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
CA2838207A1 (en) 2011-06-08 2012-12-13 Denovo Biopharma (Hangzhou) Ltd. Co. Methods and compositions of predicting activity of retinoid x receptor modulator
US20140274764A1 (en) 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
US20170253928A1 (en) 2013-03-15 2017-09-07 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
TR201907106T4 (tr) 2014-03-14 2019-06-21 Caredx Inc Bir transplant alıcısında immünosüpresif terapileri izleme yöntemleri.

Also Published As

Publication number Publication date
US12612661B2 (en) 2026-04-28
CN115515680A (zh) 2022-12-23
WO2021178166A1 (en) 2021-09-10
CA3174572A1 (en) 2021-09-10
US20230193388A1 (en) 2023-06-22
MX2022010816A (es) 2022-12-13
BR112022017770A2 (pt) 2022-11-29
JP2023515665A (ja) 2023-04-13
TW202146660A (zh) 2021-12-16
EP4106872A4 (en) 2024-04-10
EP4106872A1 (en) 2022-12-28
KR20230005816A (ko) 2023-01-10
AU2021231683A1 (en) 2022-09-22
AR121515A1 (es) 2022-06-08

Similar Documents

Publication Publication Date Title
US20210108266A1 (en) Method for discovering pharmacogenomic biomarkers
US20230074781A1 (en) Methods and composition for the prediction of the activity of enzastaurin
KR20140039278A (ko) 레티노이드 x 수용체 모듈레이터 활성 예측 방법 및 조성물
JP2022550905A (ja) circRNAを検出する方法
IL296168A (en) Preparations and methods for evaluating the effectiveness of inhibitors of neurotransmitter transporters
KR102033813B1 (ko) 항정신병약물-베이스 치료에 의하여 유발된 추체외로 증상 (eps)의 개시를 예측하는 방법
Yang et al. A large pedigree study confirmed the CGG repeat expansion of RILPL1 Is associated with oculopharyngodistal myopathy
JP2010515467A (ja) 心筋梗塞及び心不全における診断マーカー及び薬剤設計のためのプラットホーム
HK40083504A (en) Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters
Sabbatini Identificazione e caratterizzazione dei modificatori genetici della DMD
Federoff An investigation into the genetic architecture of multiple system atrophy and familial Parkinson's disease
이진숙 Whole exome sequencing-based discovery of causative genes
HK40011257B (en) Methods and composition for the prediction of the activity of enzastaurin
HK40011257A (en) Methods and composition for the prediction of the activity of enzastaurin
Chien Development of a feasible assay for the detection of GAA mutations in patients with Pompe disease
HK1196399B (en) Method for discovering pharmacogenomic biomarkers
HK1196399A (en) Method for discovering pharmacogenomic biomarkers